Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
Make a selection below to explore our full database of 7 results matching: "Osteosarcoma"
ACE Reports
(7 Reports)
ACE Reports
Originals
(0 Articles)
Originals
Podcasts
(0 Videos)
Podcasts
Our Al driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Tumour
Ifosfamide-based chemotherapy yields high survival rate for treatment of osteosarcoma
Drug Des Devel Ther. 2015 Nov 4;9:5925-32
Ifosfamide-based chemotherapy yields high survival rate for treatment of osteosarcoma
Drug Des Devel Ther. 2015 Nov 4;9:5925-32
Tumour
COA 2020: First-time Diagnosis of Osteosarcoma in a Dinosaur
COA 2020: First-time Diagnosis of Osteosarcoma in a Dinosaur
Tumour
Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide
Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide
Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30
Tumour
Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival
J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095
Includes Author Interview
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival
J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095
Tumour
Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma
J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma
J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7
Tumour
MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients
Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients
Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566
General Orthopaedics
Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
Cancer. 2012 Dec 1;118(23):5888-93
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
Cancer. 2012 Dec 1;118(23):5888-93